Related references
Note: Only part of the references are listed.Emerging therapies for haemophilia - Global perspective
J. Mahlangu et al.
HAEMOPHILIA (2018)
Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa/factor X bispecific antibody emicizumab
K. Nogami et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2018)
Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies
K. Nogami et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2018)
Emicizumab-mediated haemostatic function in patients with haemophilia A is down-regulated by activated protein C through inactivation of activated factor V
Koji Yada et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors
J. Mahlangu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Novel therapies and current clinical progress in hemophilia A
Pauline Balkaransingh et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2018)
A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A
Koichiro Yoneyama et al.
CLINICAL PHARMACOKINETICS (2018)
European retrospective study of real-life haemophilia treatment
E. Berntorp et al.
HAEMOPHILIA (2017)
Emicizumab Prophylaxis in Hemophilia A with Inhibitors
Johannes Oldenburg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Factor Villa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens
Takehisa Kitazawa et al.
THROMBOSIS AND HAEMOSTASIS (2017)
Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors
Midori Shima et al.
BLOOD ADVANCES (2017)
A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects
Naoki Uchida et al.
BLOOD (2016)
A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A
F. Peyvandi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A
Midori Shima et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Comparative Immunogenicity of TNF Inhibitors: Impact on Clinical Efficacy and Tolerability in the Management of Autoimmune Diseases. A Systematic Review and Meta-Analysis
Sarah S. Thomas et al.
BIODRUGS (2015)
Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A
Atsushi Muto et al.
BLOOD (2014)
Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation
A. Muto et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2014)
Guidelines for the management of hemophilia
A. Srivastava et al.
HAEMOPHILIA (2013)
Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor Activity
Zenjiro Sampei et al.
PLOS ONE (2013)
Factor VIII Light Chain Contains a Binding Site for Factor X That Contributes to the Catalytic Efficiency of Factor Xase
Masahiro Takeyama et al.
BIOCHEMISTRY (2012)
The principal results of the International Immune Tolerance Study: a randomized dose comparison
Charles R. M. Hay et al.
BLOOD (2012)
Intravascular recovery of VWF and FVIII following intraperitoneal injection and differences from intravenous and subcutaneous injection in mice
Q. Shi et al.
HAEMOPHILIA (2012)
A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model
Takehisa Kitazawa et al.
NATURE MEDICINE (2012)
The Factor VIIIa C2 Domain (Residues 2228-2240) Interacts with the Factor IXa Gla Domain in the Factor Xase Complex
Tetsuhiro Soeda et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Factor VIII structure and function
PJ Fay
INTERNATIONAL JOURNAL OF HEMATOLOGY (2006)
Practice patterns in haemophilia A therapy - global progress towards optimal care
S Geraghty et al.
HAEMOPHILIA (2006)
Contrasting IgG structures reveal extreme asymmetry and flexibility
EO Saphire et al.
JOURNAL OF MOLECULAR BIOLOGY (2002)
3-Dimensional structure of membrane-bound coagulation factor VIII: modeling of the factor VIII heterodimer within a 3-dimensional density map derived by electron crystallography
S Stoilova-McPhie et al.
BLOOD (2002)
Share Paper
